Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  Bausch Health Companies Inc    BHC   CA0717341071


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Bausch Health : + Lomb Announces U.S. Launch Of Ocuvite® Eye Performance Vitamins

share with twitter share with LinkedIn share with facebook
share via e-mail
07/09/2019 | 07:01am EDT

Now Available at Major U.S. Retailers

BRIDGEWATER, N.J., July 9, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced the U.S. launch of Ocuvite® Eye Performance vitamins, a nutritional supplement designed to meet the changing needs of consumers while further expanding the company's eye vitamin portfolio.

"Today's modern, always-on world has evolved faster than our eyes – from the blue light of computer screens and cell phones to the increased UV exposure from the sun – which can have an impact on our eye health," said Joe Gordon, U.S. president, Bausch + Lomb. "We developed Ocuvite Eye Performance eye vitamins to provide consumers the essential nutrients they need to strengthen the eye's natural protective filter, so that they can help support and protect their eye health."

Ocuvite Eye Performance eye vitamins were formulated with seven vital nutrients that help strengthen the macula, which protects the eye from stressors such as sun light and blue light emitted from digital devices. These seven vital nutrients include lutein and zeaxanthin, the two carotenoid pigments naturally found in the eye, omega-3's, to help support healthy tears and a healthy retina, zinc to help regulate immune function in the eye, vitamins C and E, two antioxidants key to eye health, and vitamin D, an antioxidant to help prevent inflammation.

"I often hear from patients how they are taking steps to protect their skin from the sun or making accommodations at work for the hours spent in front of their computers, but they forget that modern day life can also impact their eyes," said Jeffry D. Gerson, O.D., FAAO, Grin Eye Care, Olathe, Kansas. "I'm pleased to be able to recommend Ocuvite Eye Performance vitamins to my patients as a simple addition to their health and wellness regimen, to help nourish the macula, which helps protect their eyes from some of the stressors they encounter every day." 

Ocuvite Eye Performance eye vitamins are available for purchase at major retailers nationwide, including Walgreens, CVS, Walmart, Target and Amazon, and have a manufacturer suggested retail price of $19.99 (50 count bottle).

For more information on Ocuvite Eye Performance vitamins, visit www.ocuvite.com.

About Bausch + Lomb
Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies Inc., is a leading global eye health organization that is solely focused on helping people see. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries. For more information, visit www.bausch.com.

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.

Forward-looking Statements
This news release may contain forward-looking statements which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Bausch Health's most recent annual or quarterly report and detailed from time to time in Bausch Health's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.                                 

Ocuvite is a trademark of Bausch & Lomb Incorporated or its affiliates.
© 2019 Bausch Health Companies Inc. or its affiliates.

Bausch Health Investor/Media Contact:                                                                
Arthur Shannon                                                                                                                               
(514) 856-3855                                                                                                                               
(877) 281-6642 (toll free)

Bausch Health logo (PRNewsfoto/Bausch Health Companies Inc.)


(PRNewsfoto/Valeant Pharmaceuticals Interna)

View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch--lomb-announces-us-launch-of-ocuvite-eye-performance-vitamins-300881394.html

SOURCE Bausch Health Companies Inc.

© PRNewswire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
08/07BAUSCH HEALTH : FDA Accepts NDA For IDP-123 Lotion for Acne
08/07BAUSCH HEALTH : Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP..
08/06BAUSCH HEALTH : Management's Discussion and Analysis of Financial Condition and ..
08/06BAUSCH HEALTH : reports better Q2 results, raises 2019 estimated revenue, earnin..
08/06BAUSCH : 2Q Earnings Snapshot
08/06BAUSCH HEALTH : Increases Revenue, Adjusted Ebitda Guidance
08/06BAUSCH HEALTH : Loss Lessens As Expenses Fall
08/06BAUSCH HEALTH COMPANIES INC. : Results of Operations and Financial Condition (fo..
08/06BAUSCH HEALTH COMPANIES INC. : Announces Second-Quarter 2019 Results And Raises ..
08/01BAUSCH HEALTH : + Lomb Initiates First Clinical For Technolas Teneo Excimer Lase..
More news